License agreement with an american start-up in the treatment of anaemia and rare genetic disorders
License agreement with an american start-up in the treatment of anaemia and rare genetic disorders.
Mov’eo and Erganeo sign a partnership for the success of mobility start-ups
Marc CHARLET, CEO of the MOV'EO competitiveness cluster and Suat TOPSU, Executive Chairman of ERGANEO, signed a special partnership agreement to promote the success of mobility start-ups initiated by Erganeo.
As Askbio acquires Brainvectis, Erganeo’s first start-up flies the nest
On 17 April, Brainvectis, a start-up supported by Erganeo specialising in neurodegenerative disease treatments, was acquired by American company Asklepios BioPharmaceutical (AskBio).
Erganeo and IPEDIS® are co-investing to industrialize a technology with a strong societal impact
Erganeo, IPEDIS® and the University of Paris join forces to prepare the market launch of a technology created by IPEDIS® to make PDF documents accessible to visually impaired people.
Crawliskate®, technology backed by Erganeo and captured on film by Netflix in a documentary series about babies
Learning to walk is a milestone in every child’s life. Babies start crawling at around eight to ten months old.
SATT results: The signed licences crossed 1,000 mark!
Through their consolidated results as of January 1, 2020, the SATTs confirm the key role they play in the service of Research and the emergence of Deep Tech innovations in France.
The SATTs, catalysts of innovation, creators of value for the French economy
Two studies have just been published confirming the significant role played by SATTs in the national economy through this process of valorization of French academic research.
Erganeo signs a licensing agreement with start-up EverZom, creating a platform for the production of biological tools, extracellular vesicles
On Tuesday, 3 December, Erganeo and start-up EVerZom signed an exclusive licensing agreement for the development of an innovative extracellular vesicle bioproduction procedure.
Résultats des SATT : Une dynamique de performance au service de l’innovation
Par ses résultats consolidés au 1er juillet 2019, le Réseau SATT confirme le rôle-clé joué par les SATT au service de la Recherche et du développement économique et continue de se positionner comme une référence sur l’innovation Deep Tech en France.
Erganeo helps launch start-up Ermium Therapeutics, which has already raised €6.3m in start-up capital
From the moment it launched, through Erganeo, Kurma Partners, Idinvest Partners and Domain Therapeutics, the start-up succeeded in raising €6.3m.